Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance

Blood

Volumn 115, Issue 12, 2010, Pages 2420-2429

  Henry, Carole ^a,b,c   Deschamps, Marina ^a,b,c   Rohrlich, Pierre Simon ^a,b,c,d   Pallandre, Jean René ^a,b,c   Rémy Martin, Jean Paul ^a,b,c   Callanan, Mary ^a,e   Traverse Glehen, Alexandra ^f   GrandClément, Camille ^a,b,c   Garnache Ottou, Francine ^a,b,c,f   Gressin, Remy ^a,e   Deconinck, Eric ^a,b,c,e   Salles, Gilles ^f   Robinet, Eric ^g   Tiberghien, Pierre ^a,b,c,d   Borg, Christophe ^a,b,c,d   Ferrand, Christophe ^a,b,c,e  

^a INSERM   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS   (France)

^f UNIVERSITÉ LYON 1   (France)

^g UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; MESSENGER RNA; RITUXIMAB;

ALTERNATIVE RNA SPLICING; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS CELL TRANSFORMATION;

EID: 77950560127     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-229112     Document Type: Article

References (53)

1. Algino KM, Thomason RW, King DE, Montiel MM, Craig FE. CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. Am J Clin Pathol. 1996;106(1):78-81. (Pubitemid 26239325)
2. Liang Y, Buckley TR, Tu L, Langdon SD, Tedder TF. Structural organization of the human MS4A gene cluster on Chromosome 11q12. Immunogenetics. 2001;53(5):357-368. (Pubitemid 32762813)
3. Tedder TF, Klejman G, Schlossman SF, Saito H. Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). J Immunol. 1989;142(7):2560-2568. (Pubitemid 19098277)
4. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988;7(3):711-717.
5. Tedder TF, Schlossman SF. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. J Biol Chem. 1988; 263(20):10009-10015.
6. Polyak MJ, Li H, Shariat N, Deans JP. CD20 homo-oligomers physically associate with the B cell antigen receptor: dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem. 2008;283(27):18545-18552.
7. Popoff IJ, Savage JA, Blake J, Johnson P, Deans JP. The association between CD20 and Src-family Tyrosine kinases requires an additional factor. Mol Immunol. 1998;35(4):207-214.
8. Giles FJ, Vose JM, Do KA, et al. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol. 2003;123(5):850-857. (Pubitemid 37533297)
9. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2): 435-445. (Pubitemid 24030569)
10. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91(5):1644-1652. (Pubitemid 28110329)
11. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635-2642. (Pubitemid 39434941)
12. Edwards JC, Leandro MJ, Cambridge G. B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans. 2002;30(4):824-828. (Pubitemid 35001668)
13. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756-762. (Pubitemid 44061381)
14. Verschuuren EA, Stevens SJ, van Imhoff GW, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation. 2002;73(1):100-104. (Pubitemid 34094694)
15. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant. 2004;4(6): 996-1001.
16. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res. 2008;14(5):1550-1560.
17. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758. (Pubitemid 34525533)
18. Dworzak MN, Schumich A, Printz D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008;112(10):3982-3988.
19. Jilani I, O'Brien S, Manshuri T, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003;102(10):3514-3520. (Pubitemid 37419939)
20. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14(5):1561-1570. (Pubitemid 351413941)
21. Terui Y, Mishima Y, Sugimura N, et al. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Clin Cancer Res. 2009; 15(7):2523-2530.
22. Tomita A, Hiraga J, Kiyoi H, et al. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol. 2007; 86(1):49-57. (Pubitemid 47204490)
23. Sugimoto T, Tomita A, Shimada K, et al. Relationship between post-translational modification of CD20 protein and the responsiveness to rituximab treatment [abstract]. Blood. 2008;112:Abstract 2667.
24. van Meerten T, Claessen MJ, Hagenbeek A, Ebeling SB. The CD20/alphaCD20 'suicide' system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells. Gene Ther. 2006;13(9): 789-797.
25. Serafini M, Manganini M, Borleri G, et al. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum Gene Ther. 2004;15(1):63-76. (Pubitemid 38147189)
26. Introna M, Barbui AM, Bambacioni F, et al. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther. 2000; 11(4):611-620. (Pubitemid 30134304)
27. Grosso AR, Martins S, Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep. 2008;9(11):1087-1093.
28. Garin MI, Garrett E, Tiberghien P, et al. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood. 2001;97(1):122-129. (Pubitemid 32061251)
29. Ibisch C, Saulquin X, Gallot G, et al. The T cell repertoire selected in vitro against EBV: diversity, specificity, and improved purification through early IL-2 receptor alpha-chain (CD25)-positive selection. J Immunol. 2000;164(9):4924-4932. (Pubitemid 30238098)
30. Ferrand C, Robinet E, Contassot E, et al. Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire. Hum Gene Ther. 2000;11(8):1151-1164. (Pubitemid 30331581)
31. Technical University of Denmark Center for Biological Sequence Analysis. NetGene2 release 2.4. Available at: http://www.cbs.dtu.dk/services/ NetGene2. Accessed July 25, 2007.
32. University of California Berkeley Drosophila Genome Project. NNsplice v0.9. Available at: http:// www.fruitfly.org/seq-tools/splice.html. Accessed August 27, 2003.
33. Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res. 2006; 30(5):625-631. (Pubitemid 43374591)
34. National Center for Biotechnology Information (NCBI). GenBank. Available at: http://www.ncbi. nlm.nih.gov/Genbank/. Accessed March 25, 2005.
35. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood. 2006;108(6):1975-1978.
36. Liang Y, Tedder TF. Identification of a CD20-,FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. Genomics. 2001;72(2):119-127. (Pubitemid 32242951)
37. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172(5):3280-3288.
38. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18(17):3135-3143.
39. Renaudineau Y, Hillion S, Saraux A, Mageed RA, Youinou P. An alternative exon 1 of the CD5 gene regulates CD5 expression in human B lymphocytes. Blood. 2005;106(8):2781-2789. (Pubitemid 41510754)
40. Iacobucci I, Lonetti A, Messa F, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood. 2008;112(9):3847-3855.
41. Johnson NA, Boyle M, Bashashati A, et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood. 2009;113(16):3773-3780.
42. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol. 2000;27(6 suppl 12): 17-24.
43. Sar A, Perizzolo M, Stewart D, Mansoor A, Difrancesco LM, Demetrick DJ. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients. Leuk Res. 2009;33(6): 792-797.
44. Johnson NA, Leach S, Woolcock B, et al. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica. 2009;94(3):423-427.
45. Kirschbaum-Slager N, Lopes GM, Galante PA, Riggins GJ, de Souza SJ. Splicing factors are differentially expressed in tumors. Genet Mol Res. 2004;3(4):512-520. (Pubitemid 40318045)
46. Brinkman BM. Splice variants as cancer biomarkers. Clin Biochem. 2004;37(7):584-594.
47. Kapur R, Ebeling S, Hagenbeek A. B-cell involvement in chronic graft-versus-host disease. Haematologica. 2008;93(11):1702-1711.
48. Thaunat O, Patey N, Gautreau C, et al. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation. 2008;85(11): 1648-1653.
49. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol. 2007;8(4):349-357. (Pubitemid 46464532)
50. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer. 2005;5(6):468-479.
51. Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 2007;21(11):2287-2295. (Pubitemid 350011701)
52. Grube M, Rezvani K, Wiestner A, et al. Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies. Clin Cancer Res. 2004;10(3):1047-1056. (Pubitemid 38198906)
53. Daydé D, Ternant D, Ohresser M, et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modelling using a syngeneic bioluminescent murine model expressing human CD20. Blood. 2009;113(16):3765-3772.